Health Canada - Federal department responsible for drug approvals and health regulation in Canada
仅限当前页。暂不支持搜索完整审批数据集。
药物名称 | 公司 | 适应症 | 日期 | 类型 |
|---|---|---|---|---|
| SERTRALINE | altamed pharma | Marketed | Apr 9, 2024 | Marketed |
| TD ADSORBED | Sanofi Pasteur Limited | Marketed | Apr 9, 2024 | Marketed |
| OLUMIANT | eli lilly canada inc | Marketed | Apr 9, 2024 | Marketed |
| NRA-OLANZAPINE ODT | NORA PHARMA INC | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | NORA PHARMA INC | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE ODT | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE ODT | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE ODT | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| MINT-MEXILETINE | mint pharmaceuticals inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| NRA-OLANZAPINE | nora pharma inc | Marketed | Apr 8, 2024 | Marketed |
| OLOPATADINE 0.2% | sanis health inc | Marketed | Apr 8, 2024 | Marketed |
| BIO-PREGABALIN | biomed pharma | Marketed | Apr 8, 2024 | Marketed |
| SUPREME HYDRATING FACIAL SCREEN | GRACE & FIRE PTY LTD | Marketed | Apr 5, 2024 | Marketed |
| HYRIMOZ | Sandoz Canada, Inc. | Marketed | Apr 5, 2024 | Marketed |
| RYMTI | lupin pharma canada limited | Marketed | Apr 5, 2024 | Marketed |
| RYMTI | lupin pharma canada limited | Marketed | Apr 5, 2024 | Marketed |
